pembrolizumab biosimilar / NeuClone, Serum Institute of India - LARVOL DELTA

Dose escalation study of a personalized peptide-based neoantigen vaccine (EVX-01) in patients with metastatic melanoma. (PubMed, J Immunother Cancer) - P1/2 | "Immunization with EVX-01-CAF09b in addition to anti-PD-1 therapy was shown to be safe and well tolerated and elicit vaccine neoantigen-specific CD4+and CD8+ T cell responses at all dose levels. In addition, objective tumor responses were observed in 67% of patients. The results encourage further assessment of the antitumor efficacy of EVX-01 in combination with anti-PD-1 therapy."

Journal • Metastases • Tumor-specific neoantigens • Melanoma • Oncology • Solid Tumor • CD4 • CD8 • IFNG

Final results: Dose escalation study of a personalized peptide-based neoantigen vaccine in patients with metastatic melanoma. (ASCO 2023) - P1/2 | "Here, we report on a first-in-human clinical trial evaluating a personalized neoantigen vaccine (EVX-01) in patients with metastatic melanoma...All patients received monotherapy with pembrolizumab (11) or nivolumab (1) during the vaccine manufacturing period... aPD-1 treatment combined with a peptide-based personalized neo-antigen-based vaccine was shown to be feasible and safe with promising signs of efficacy, warranting further study. Further, the neo-antigen selection method appeared crucial for designing an efficacious vaccine. Clinical trial information: NCT03715985."

Clinical • Metastases • Tumor-specific neoantigens • Fatigue • Melanoma • Oncology • Solid Tumor • CD4